Prometheus | Mamacrowd

TAX Bonus

Innov SME



Prometheus 2

Medical Devices

Customized medical devices applied for the treatment of chronic wounds, cartilage injuries, and aesthetic medicine.

  • Technology protected by 5 patents

  • Passed preclinical testing for CE marking

  • Commercial collaboration with B.Braun (multinational +7Bn€ turnover)

  • After the first crowd collection developed new products for the veterinary line

Professional Investor

Professional Inv.

Goal min 1,6 Mln€

Goal max 2,6 Mln€

Total Collected

2,7 Mln€




21,2 Mln€

Minimum goal

1,6 Mln€

Minimum Order

498,15 €



  • Project
  • Market and Target
  • Business Model
  • Financial projections
  • Use of funds
  • Team
immagine copertina


Prometheus develops medical devices in veterinary and hospital regenerative medicine.

Thanks to a record €1 Mln raise conducted in 2021 on Mamacrowd (overfunded in just 2 days), the company started the certification of its devices for human use, successfully completed the preclinical phase, and expanded its veterinary product range.

In fact, the company is already present in the veterinary market with the Ematik line, thanks to the commercial collaboration started in November 2022 with an industry leader: B. Braun, a multinational company with +7Bn € in sales.

The products of the Ematik range are based on the use of blood (processed with a machine developed in-house), combined with different resorbable biomaterials, diversified according to the application:

  • Orthopedics kit (cartilage, tendon and ligament regeneration)
  • Dentistry kit (maxillofacial reconstructions)
  • Ophthalmology kit (corneal ulcers)
  • Vulnology kit (wound treatment)
  • Aesthetic medicine kit (wrinkle treatment and hair regrowth-no vet).

All products, which are already successfully used in the animal field, have the possibility of being translocated to the hospital market as well.

The efficacy and safety data of the products for orthopedics, dentistry, and aesthetic medicine have already been submitted to the relevant bodies, and at the end of 2023 it is planned to obtain the CE mark, so as to start sales in hospitals.

The company's flagship product is Ematik Patch, a customized patch for severe injuries (sores and ulcers), which uses the patient's own blood combined with biomaterials that can cut healing time in half.

In order to initiate commercialization of the Patch, regulations require a human study, the central reason for this capital raise.

The patch acts like a second skin:

  • Accelerates regeneration, halving the time required for wound closure
  • Avoids scarring and adverse events
  • Reduces the risk of infection, with antimicrobial activity
  • Is absorbed into the skin, with no need for painful manipulation to remove it.

The patch is obtained by the physician through a fully automated system: a machine that extracts the active molecules from the blood in a process of minutes and combines them with biomaterials supplied to the physician in a disposable kit, allowing the physician to obtain the medicine to be applied to the wound.

The amazing results have been demonstrated by healing numerous animal clinical cases in collaboration with the Departments of Veterinary Medicine at the Universities of Parma and Perugia and by customers already purchasing the product.

The project was supported by experts in the field, such as Dr. Antonino Di Pietro of the Vita Cutis Clinic and Dr. Pasquale Longobardi of the Ravenna Hyperbaric Center.

Tax benefits of 30 percent apply on Prometheus .

On the campaign is available the optional Rubrication free of charge for the Investor as the costs are borne by Prometheus.

Prometheus reserves the right of "liquidation preference" for all investors who join the campaign, who will therefore be reimbursed first in the event of an exit than the company's other shareholders (according to the order of preference indicated in the bylaws). All conditions are published in the bylaws found in the Documents section.


Want to find out more about this project?

Do you already have an account?

Prometheus 2

The information on the offer is not subject to approval by Consob. The Offering company is solely responsible for the completeness and truthfulness of the data and information provided by the latter. The investor's attention is also drawn to the fact that the investment, even indirect, through OICR or companies that invest mainly in financial instruments issued by innovative startups and SMEs is illiquid and characterised by a very high risk.

By using the services of Mamacrowd you accept our cookies policy. We and our partners operate globally and use cookies, including for statistical, advertising and customisation purposes.

Show preferences